Innovus Pharma Announces the Launch of its Hemorrhoid Drug Xyralid in Canada

Innovus Pharmaceuticals announced the launch of its lidocaine-based cream Xyralid, for the relief of pain and symptoms caused by hemorrhoids. Xyralid received a Product License Application in Canada and the product is available as an over-the-counter or behind the counter drug and will not require a prescription. The product is available in Canada directly through the Company’s website and through its Beyond Human marketing and sales platform.

“We are very happy to announce the launch of Xyralid in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Xyralid represents the second product launched through our own sales and marketing commercial efforts in Canada in addition to Apeaz and is our sixth product on the Canadian market including Zestra, Zestra Glide and Uxor (EjectDelay) marketed by Orimed Pharma and UriVarx through our partnership with Acerus Pharmaceuticals Corporation.”